Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EBT (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EBT for 4 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 7.25% to -$2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$606068.0, a 87.74% increase, with the full-year FY2024 number at -$583381.0, up 27.68% from a year prior.
  • EBT was -$2.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, down from -$1.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.3 million in Q4 2024 to a low of -$4.2 million in Q2 2024.
  • A 4-year average of -$813068.6 and a median of -$1.8 million in 2025 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 1806.68% in 2023, then plummeted 538.56% in 2025.
  • 60 Degrees Pharmaceuticals' EBT stood at -$1.7 million in 2022, then skyrocketed by 157.53% to $960705.0 in 2023, then surged by 454.03% to $5.3 million in 2024, then plummeted by 143.53% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EBT are -$2.3 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.9 million (Q1 2025).